ozoralizumab   Click here for help

GtoPdb Ligand ID: 9638

Synonyms: ATN-103 | PF-5230896
Immunopharmacology Ligand
Compound class: Antibody
Comment: Ozoralizumab is a trivalent albumin-binding nanobody that binds to and neutralises circulating TNFα. This biologic agent is being investigated for anti-inflammatory potential. The peptide sequence for ozoralizumab submitted in its WHO INN record is identical to SEQ ID NO: 96 (TNF30) in patent US8703131 [1], and identifies the albumin nanobody as ALB8. The patent claims a trivalent construct of TNF30-linker-ALB8-linker-TNF30.
Immunopharmacology Comments
Ozoralizumab neutralises pro-inflammatory TNFα; TNFα being a causative immune modulator that exacerbates symptoms of rheumatoid arthritis and other autoimmune diseases.
Immunopharmacology Disease
Disease X-Refs Comment References
Rheumatoid arthritis Disease Ontology: DOID:7148
OMIM: 180300
Ozoralizumab has completed proof-of-concept Phase II clinical trial in RA (NCT00959036- in patients on a background of methotrexate)